CORCEPT THERAPEUTICS INC Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
CORCEPT THERAPEUTICS INC (CORT) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $21.32 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $21.32M, a 10.95% increase year-over-year.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $10.10M, a 52.09% decline year-over-year.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $13.89M, a 29.48% decline year-over-year.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $19.22M, a 207.93% increase year-over-year.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $97.50M, a 124.15% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $43.50M, a 34.15% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $32.42M, a 29.11% decline from fiscal 2022.
- CORCEPT THERAPEUTICS INC share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $45.74M, a 18.39% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.32M 10-Q · filed 2026-07-29 | $31.43M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2026-03-31 | $10.10M 10-Q · filed 2026-07-29 | |||
| 2025-12-31 | $97.50M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $13.89M 10-Q · filed 2025-11-04 | $33.12M derived: sum of 2 quarters · filed 2026-07-29 | $54.20M derived: sum of 3 quarters · filed 2026-07-29 | |
| 2025-06-30 | $19.22M 10-Q · filed 2026-07-29 | $40.31M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2025-03-31 | $21.09M 10-Q · filed 2026-07-29 | |||
| 2024-12-31 | $43.50M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $19.70M 10-Q · filed 2025-11-04 | $25.95M derived: sum of 2 quarters · filed 2025-11-04 | $29.50M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $6.24M 10-Q · filed 2025-11-04 | $9.80M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $3.55M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $32.42M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $17.87M 10-Q · filed 2024-10-30 | $22.69M derived: sum of 2 quarters · filed 2024-10-30 | $29.05M derived: sum of 3 quarters · filed 2024-10-30 | |
| 2023-06-30 | $4.82M 10-Q · filed 2024-10-30 | $11.18M derived: sum of 2 quarters · filed 2024-10-30 | ||
| 2023-03-31 | $6.36M 10-Q · filed 2024-10-30 | |||
| 2022-12-31 | $45.74M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $26.19M 10-Q · filed 2023-11-01 | $35.55M derived: sum of 2 quarters · filed 2023-11-01 | $42.59M derived: sum of 3 quarters · filed 2023-11-01 | |
| 2022-06-30 | $9.37M 10-Q · filed 2023-11-01 | $16.40M derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | $7.04M 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $38.63M 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $4.27M 10-Q · filed 2022-11-03 | $7.50M derived: sum of 2 quarters · filed 2022-11-03 | $30.02M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $3.24M 10-Q · filed 2022-11-03 | $25.76M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $22.52M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $3.15M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $155.00K 10-Q · filed 2021-11-03 | $990.00K derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-06-30 | $835.00K 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $8.07M 10-K · filed 2022-02-15 | |||
| 2019-03-31 | $5.10M 10-Q · filed 2020-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |